|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylglyoxal (MGO) is a glycolysis byproduct that accumulates in DM and is detoxified by the Glyoxalase 1 (Glo1).
|
30342159 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data show that maternal diabetes mellitus affects the specific activity of GLO1, indicating that GLO1 was post-translationally modified due to changes in metabolic processes in the preimplantation embryos.
|
31512318 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative RT-PCR revealed that bergenin decreased the expression of ERK1, Akt2, MMP-9, and OSTM1 genes in the presence of MG. Bergenin pretreatment yielded significant increases in intracellular calcium concentration, mitochondrial mass, mitochondrial membrane potential, and glyoxalase I reduced by MG. Additionally, bergenin decreased the formation of mitochondrial superoxide induced by MG. Detoxification of MG by bergenin may be a viable treatment for bone disorders in patients with diabetes.
|
31369791 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CKD decreases <i>GLO1</i> gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.
|
29783710 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the effect of quercetin on brain damage that was caused by diabetes in rats and the mechanisms associated with Glo-1.
|
30062553 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, MG scavengers (such as N-acetylcysteine, aminoguanidine or metformin) or Nrf2/Glo1 activators (such as trans-resveratrol / hesperetin) are shown to be useful in preventing MG-induced cardiovascular and renal complications in diabetes.
|
30179128 |
2018 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This review focuses on the current understanding of MGO accumulation and Glo1 activity in diabetes, and their contribution on the impairment of endothelial function leading to diabetes-associated vascular damage.
|
28106778 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study showed that mangiferin could attenuate diabetes-associated cognitive impairment of rats by enhancing the function of glyoxalase 1 (Glo-1) in brain.
|
27318675 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glo1 inducers are in development to sustain healthy aging and for treatment of vascular complications of diabetes and other disorders, and cell-permeant Glo1 inhibitors are in development for treatment of multidrug-resistant tumours, malaria and potentially pathogenic bacteria and fungi.
|
24646254 |
2014 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates that protection from MG uniquely in BM is sufficient to restore BMC function and neovascularization of ischaemic tissue in diabetes and identifies GLO1 as a potential therapeutic target.
|
24259499 |
2014 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In a multiple regression analysis with GLO1 activity as the dependent variable, including the Ala111Glu polymorphism, the significant independent variables were log GSSG (ß - 0.318, p = 0.02) and HbA1c (ß 0.285, p = 0.041) in the diabetes group and log GSH, (ß 0.407, p = 0.004) in the control group.
|
23360186 |
2013 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SNPs in GLO1 can be used to predict enzyme activity and detoxifying capabilities, but further studies are needed to link these SNPs with common complications in diabetes.
|
23201419 |
2013 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Diabetes was induced in wild-type (WT) and GLO1 rats and the animals were killed after 12 or 24 weeks of hyperglycaemia.
|
22143324 |
2012 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, we developed a flow cytometry method for GLO-1 detection in human leukocytes isolated from peripheral blood samples to investigate GLO-1 expression in leukocyte subsets from type 1 and 2 diabetes mellitus patients (n = 11) and healthy subjects (n = 8).
|
21370249 |
2011 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study shows for the first time in an in vivo model of diabetes that GLO-I overexpression reduces hyperglycemia-induced levels of carbonyl stress, AGEs, and oxidative stress.
|
21056979 |
2011 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accumulative evidence suggests an important role of GLO1 expression in protection against methylglyoxal-dependent protein adduction and cellular damage associated with diabetes, cancer, and chronological aging.
|
20093988 |
2010 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The diabetes-induced impaired potency (pD(2)) in mesenteric arteries of wild-type rats was significantly improved by GLO-I overexpression (p < 0.05).
|
20186387 |
2010 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present study was conducted to explore the hypothesis that specific polymorphisms of the Glo1 gene are associated with diabetes and/or albuminuria in Zuni Indians.
|
18413187 |
2008 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
|
6892568 |
1980 |